Health Care

Explore how United Therapeutics’ insider trade by President Benkowitz reveals a disciplined Rule 10b5‑1 strategy, a stable pipeline, and a forward‑looking stance on reimbursement and tech trends.

Solid Biosciences CFO buys shares, signaling confidence in neuromuscular drug pipeline and future growth.

Insider buying by Dentsply Sirona’s CEO signals confidence in long‑term value despite low prices, negative earnings, and competitive dental‑equipment market.

ClearPoint Neuro CEO’s 10b5‑1 buys signal confidence in neuro‑cell & gene therapies, aligning management with investors amid strong earnings and value‑based reimbursement trends.

HealthEquity insider sales on Jan 9, 2026 reveal execs taking profit amid a 7% stock dip, sparking investor scrutiny and mixed analyst views.

Discover how Paul Friedman’s January 9 trade on Madrigal Pharmaceuticals reflects a balanced long‑term conviction amid short‑term profit‑taking, and why the company’s pipeline and pricing strategy could drive future gains.

Insider buying at Agilon Health shows management confidence amid volatile shares and signals potential upside as the company expands its senior‑care network and tech‑enabled care model.

Cooper Cos insider filings show long‑term trust confidence and balanced exec trading, hinting at steady growth in diagnostics and contact lenses.

Insider buying at DENTSPLY SIRONA signals cautious optimism: small RSU purchases reveal management’s confidence in a cost‑cutting turnaround and steady growth in digital dentistry.

Liquidia Corp’s insider buying shows management confidence, aligning with a recent earnings beat and a promising nanoparticle platform—an optimistic signal for investors.